USP 800 – Community Pharmacy Compliance

Do you stock azathioprine tablets? What about carbamazepine oral suspension, or methotrexate injectable solution? If you don’t stock these, then surely you stock clonazepam tablets or oral contraceptives. These are just a few of the 400+ hazardous drugs (HDs) identified by the National Institute for Occupational Safety and Health (NIOSH) as per the most recent NIOSH list published in 2024. Stocking any of these medications means that USP 800 compliance applies to your pharmacy.

Many people mistakenly believe that USP 800 is only required when compounding with hazardous drugs; however, all healthcare professionals that “handle” HDs must comply with USP 800 to reduce the risk of occupational exposure and keep your employees safe. Independent community pharmacies that receive, store, dispense, package, or dispose of hazardous drugs (collectively referred to as “handling”) should have procedures in place to protect employees and patients.

Key Steps for Compliance

  1. Create and maintain a Hazardous Drug List and review it annually
  2. Develop written Policies and Procedures that outline your work practices for handling hazardous drugs
  3. Perform and document Risk Assessments for each hazardous drug/dosage form
  4. Purchase or create a Spill Kit to handle spills safely
  5. Wear Personal Protective Equipment (PPE) as determined by your policies and risk assessment
  6. Train your staff on safe handling practices, PPE, and spills (complete prior to handling hazardous drugs and then annually)

USP 800 is an ongoing responsibility, and pharmacies should be re-evaluating their compliance at least annually.

PAAS Tips:

  • Pharmacies interested in a turnkey USP 800 Compliance Program should review program details on the PAAS National® website or call (608) 873-1342 for additional information.
    • The PAAS program is not intended for pharmacies that are compounding with hazardous drugs.
  • For pharmacies that already utilize PAAS’ USP 800 program, ensure that you have reviewed the hazardous drug list based on the most recent NIOSH changes
    • NIOSH added three additional products to Table 1 in July 2025 due to manufacturer special handling information (MSHI) which has been incorporated into the program
    • Now is a good time to review the web-based “Assessments of Risk” on the PAAS Portal to update your hazardous drug list as well as review and finalize/sign your annual Assessments of Risk

Eric Hartkopf, PharmD